Parkinson's disease (PD) is a genetically complex disorder. Multiple genes have been shown to contribute to the risk of PD, and currently 90 independent risk variants have been identified by genome-wide association studies. Thus far, a number of genes (including SNCA, LRRK2, and GBA) have been shown to contain variability across a spectrum of frequency and effect, from rare, highly penetrant variants to common risk alleles with small effect sizes.
Abstract
Parkinson's disease (PD) is a genetically complex disorder. Multiple genes have been shown to contribute to the risk of PD, and currently 90 independent risk variants have been identified by genome-wide association studies. Thus far, a number of genes (including SNCA, LRRK2, and GBA) have been shown to contain variability across a spectrum of frequency and effect, from rare, highly penetrant variants to common risk alleles with small effect sizes.
Variants in GBA, encoding the enzyme glucocerebrosidase, are associated with Lewy body diseases such as PD and Lewy body dementia (LBD). These variants, which reduce or abolish enzymatic activity, confer a spectrum of disease risk, from 1.4-to >10-fold. An outstanding question in the field is what other genetic factors that influence GBA-associated risk for disease, and whether these overlap with known PD risk variants.
Using multiple, large case-control datasets, totalling 217,165 individuals (22, 757 PD cases, 13 ,431 PD proxy cases, 622 LBD cases and 180,355 controls), we identified 1,772 PD cases, 711 proxy cases and 7,624 controls with a GBA variant (p.E326K, p.T369M or p.N370S). We performed a genome-wide association study and analysed the most recent PD-associated genetic risk score to detect genetic influences on GBA risk and age at onset. We attempted to replicate our findings in two independent datasets, including the personal genetics company 23andMe, Inc. and whole-genome sequencing data. Our analysis showed that the overall PD genetic risk score modifies risk for disease and decreases age at onset in carriers of GBA variants. Notably, this effect was consistent across all tested GBA risk variants. Dissecting this signal demonstrated that variants in close proximity to SNCA and CTSB (encoding cathepsin B) are the most significant contributors. Risk variants in the CTSB locus were identified to decrease mRNA expression of CTSB. Additional analyses suggest a possible genetic interaction between GBA and CTSB and GBA p.N370S neurons were shown to have decreased Cathepsin B expression compared to controls. These data provide a genetic basis for modification of GBA-associated PD risk and age at onset and demonstrate that variability at genes implicated in lysosomal function exerts the largest effect on GBA associated risk for disease. Further, these results have important implications for selection of GBA carriers for therapeutic interventions.
Introduction
Heterozygous functional GBA variants are one of the most common genetic risk factors for Parkinson's disease (PD) and Lewy body dementia (LBD), found in 3-20% of patients in different populations (Blauwendraat et al. 2018b; Gan-Or et al. 2015c; Guerreiro et al. 2018; Lesage et al. 2011; Rivas et al. 2018 ). In a homozygous or compound heterozygous state, GBA variants may cause Gaucher disease, an autosomal recessive lysosomal storage disorder.
GBA encodes the lysosomal enzyme glucocerebrosidase (GCase), and it is hypothesized that loss of GCase activity leads to a reduced ability to degrade α -synuclein, encoded by SNCA.
Aggregated, misfolded α -synuclein protein deposits in the form of Lewy bodies and Lewy neurites are the pathological hallmarks of PD and LBD.
Notably, GBA variants that do not cause Gaucher disease but do confer increased risk for PD and LBD have been identified. It is hypothesized that while these variants result in reduced GCase activity, the activity is not low enough to cause Gaucher disease. Multiple rare GBA variants have been described in PD in different populations. More common variants include p.E326K, p.T369M, p.N370S and p.L444P, whose frequencies vary with ethnicity and are each found on different haplotypes (Blauwendraat et al. 2018b; Leija-Salazar et al. 2019 In recent years, GBA has become a prominent target for therapeutic development, and the first gene-specific phase 2 clinical trial in PD is currently ongoing for GBA-positive PD patients (ClinicalTrials.gov Identifier: NCT02906020). One of the concerns in performing such a trial is that, despite the randomization for treatment and placebo groups, these groups will remain unbalanced in terms of factors that affect their progression, which can be a significant confounder of trial outcome (Leonard et al. 2018 ). In addition, it is likely that future preventive clinical trials will also target populations that are at high risk for Lewy body diseases, such as GBA risk variant carriers with prodromal symptoms. Therefore, identifying factors that can affect the penetrance and clinical presentation of GBA-associated PD will be crucial for trial design. Furthermore, modifiers of penetrance AAO may also become drug targets.
In the current study, we gathered data from multiple sources, including the International Parkinson's Disease Genomics Consortium (IPDGC) and the UK Biobank (UKB), to identify GBA variants in both cases and controls and used 23andMe and whole-genome sequencing data for further validation. Subsequently, we used genome-wide association studies (GWAS) and genetic risk scoring to identify genetic variants that modify the penetrance and AAO of GBA-associated PD. We then examined protein levels of the top hits in forebrain neurons differentiated from iPS cells of individuals with and without GBA variants.
Materials and methods

Genotyping data
International Parkinson Disease Genomics Consortium genotyping data
Genotyping data (all Illumina platform based) was obtained from International Parkinson's Disease Genomics Consortium (IPDGC) members, collaborators, and public resources (Supplementary Table 1 and 2). All datasets underwent quality control separately, both on individual-level data and variant-level data before imputation as previously described (Blauwendraat et al. 2019; Nalls et al. 2018 ). Refer to Supplementary data for a detailed description of data processing.
For GWAS analyses, variants passing the following post-imputation criteria were included: R 2 > 0.8, minor allele frequency > 0.05, and genotype missingness < 0.15 across subsets.
Case-control GWAS were performed using RVTESTS with default settings (Zhan et al. 2016 ) using logistic regression with sex, age (if not available the mean age of all data was used), principal components (PC) 1-5, and dataset origin as covariates. AAO GWAS was performed in GBA carriers only using RVTESTS linear regression with AAO as a continuous phenotype and sex, PC 1-5 and dataset origin as covariates. Cases without age information were excluded from the AAO GWAS, and individuals with two GBA variants were excluded from all analyses to prevent bias (Supplementary Table 2 ).
Lewy body dementia genotyping data
LBD cases and controls were genotyped for ongoing projects at the Neurodegenerative Diseases Research Unit (NDRU) using the NeuroChip genotyping array (Illumina, San Diego, CA, USA). Genotyping was performed as previously described (Blauwendraat et al. 2017 ). All cases met the McKeith criteria for probable or definite disease (McKeith 2006) .
For more details on this dataset, see Supplementary Table 2 . Genotype quality control, processing, and analysis was performed similar to the above described IPDGC genotype data.
For analyses, variants that passed the following post-imputation criteria were included: Sheba Medical Center, Ramat Gan, Israel (Ruskey et al. 2019 ). Genotype quality control, processing, and analysis was performed similar to the above described genotyping data.
UK Biobank data
Imputed UKB genotype data (v3) was downloaded (April 2018) under application number 32663 (Bycroft et al. 2018; Sudlow et al. 2015) . All European ancestry individuals (based on code 22006) were screened for the common GBA coding variants p.E326K, p.T369M (both directly genotyped) and p.N370S (imputed R 2 =0.81). PD cases were identified using ICD10 code "G20" from data fields 41202 (Diagnoses -main ICD10), 41204 (Diagnoses -secondary ICD10) and 40002 (Contributory (secondary) causes of death: ICD10). Additionally, selfreport PD cases were included from data field 20002 with code "1262". "Proxy" PD cases were included by using individuals who reported a parent with PD (paternal PD, data field 20107 and maternal PD, data field 20110) which have been previously shown to share genetic risk with PD cases (Nalls et al. 2018 ). Controls were set as people with no report of PD, no parent with PD and no sibling with PD (data field 20111). Covariates were obtained from the data fields: genetic sex (22001) batch (22000), age of recruitment (21022), and
Townsend index (189). Individuals were filtered for relatedness (PIHAT>0.125) based on the pre-imputed data. Imputed genotypes were converted to PLINK2 .pgen files using PLINK2
(version v2.00) and filtered for missingness (<0.05) and minor allele frequency (>0.05),
Hardy-Weinberg equilibrium of P ≥ 1E-6 in controls and imputation quality (R 2 > 0.8).
GWAS was performed using PLINK2 logistic regression with covariates including batch, age of recruitment, Townsend index, and 5 PCs created using FlashPCA (Abraham et al. 2017 ).
All UKB analyses were performed using population controls with age of recruitment ≥ 60 and for GBA carrier case-control analyses, the case-control ratio was set to 1:9 by randomly selected controls.
Additional datasets
Additional results for variants of interest were obtained from 23andMe and whole-genome sequencing data obtained from various resources. Analyses were performed using similar and identical methods as described above. Associations in 23andMe were performed using logistic regression correcting for age, sex, genotyping platform (v4 or v5) and 5 PCs.
Genome-sequencing data was obtained from multiple ongoing projects at the Laboratory of Neurogenetics, see Supplemental Data for a detailed description. Sample sizes can be found in Supplementary Table 3 .
Genetic risk score analyses
To assess the influence of the genetic risk score (GRS), we calculated the GRS using the effect sizes from the most recent PD GWAS variants (Nalls et al. 2018 ) (see Supplementary   Table 4 ). Note that most of the data are included in the latest PD GWAS, however, for the calculation of the GRS in the UKB data we excluded the UKB summary statistics. Overall, at least 65 of these variants of interest were imputed with high quality (R 2 > 0.8) in the included datasets, allowing for a maximum of 15% variant missingness across any constituent data subset due to differing genotyping backbones. For the IPDGC dataset, rs356182 was replaced by rs356219, due to a higher imputation quality (R 2 > 0.82 and D' 0.959 between variants in the IPDGC reference panel). Variants from the GBA locus and LRRK2 p.G2019 were excluded from the GRS in analyses including GBA carriers only. The GRS was calculated and processed using PLINK (v1.90) for each individual as described previously (Nalls et al. 2015a ). To make the scale of analyses relating to the PD-GRS more easily interpretable, PD-GRS were converted to Z-scores. GRS associations were performed with a logistic regression in R (v3.5.1) using case-control status or linear regression with AAO as the outcome phenotype. As covariates, we included: sex, age (in case-control status comparison only), the first 10 PCs, and the dataset origin (due to the fact that the IPDGC data is derived from multiple sources see Supplementary Table 2 ). Area under the curve risk predictions based on the GRS were performed using the pROC package (Robin et al. 2011) .
Additional analyses
GBA variants were annotated using ANNOVAR (Wang et al. 2010) . Nucleotide positions in GBA were based on build hg19 and amino acid positions were based on NM_001005742.
Note that historically these GBA variants are also known as p.E365K → p.E326K (rs2230288), p.T408M → p.T369M (rs75548401), and p.N409S → p.N370S (rs76763715).
Where possible, association results were meta-analysed with METAL (v.2011-03-25) using default settings (Willer et al. 2010) or using the metaphor R package (2.0) using fixed effects models (Viechtbauer 2010) . We excluded SNPs with a heterogeneity I 2 statistic > 80% and variants that were present in only one GWAS. Limited population stratification was seen despite low sample numbers in some GWAS ( Supplementary Table 5 ). Differences in AAO between GBA variants was tested using linear regression in R using AAO as the dependent variable, correcting for sex, PCs 1-5, and the dataset origin as covariates. Conditional GCTAcojo analyses (Jian Yang et al. 2011; J. Yang et al. 2012 ) were performed to identify whether there were multiple independent signals in loci of interest, using the previously described IPDGC reference panel (Blauwendraat et al. 2019; Nalls et al. 2018) . Genetic interaction analyses were performed using R (version 3.5) using an interaction term created using SNP1+1 * SNP2+1, followed by a regression using both variants and covariates (PC1-5, sex and age if available).
Exploratory gene expression values and functional annotation of identified risk variants were obtained by mining datasets including: the largest brain eQTL study to date (Qi et al. 2018) ,
the GTEx QTL portal V7 (https://gtexportal.org/) (Consortium 2013 ) and the NABEC dataset (phs001300.v1.p1, (Gibbs et al. 2010) ). LocusZoom (Pruim et al. 2010) and LocusCompare plots (B. Liu et al. 2019) were generated for the regions of interest and were compared to the latest published PD GWAS. Single-nuclei RNAseq expression of three frozen prefrontal cortex samples and four frozen hippocampal samples were obtained from dbGaP accession phs000424.v8.p1 (Habib et al. 2017) . Data was processed using Seurat and genes of interest were highlighted to explore expression patterns (Butler et al. 2018) .
GBA variant validation
To validate the genotyping and imputation of GBA variants, we obtained next-generation sequencing (targeted resequencing and genome sequencing) data from two parallel IPDGC projects. GBA carrier genotypes were merged using PLINK (v1.90) with both the resequencing and whole genome sequencing data. Overlapping individuals were identified using > 0.9 PIHAT values. Additionally, the majority of the PROBAND dataset individuals were Sanger sequenced for the full GBA gene as described elsewhere (Malek et al. 2018 ). In the McGill dataset, GBA variants were confirmed using Sanger sequencing or targeted next generation sequencing as previously described (Ruskey et al. 2019) . Overall, the concordance rate between the imputed/genotype data and the sequence data for the presence of at least one p.N370S and p.T369M allele was 100% and for p.E326K was 98% and 94% in the nextgeneration and Sanger sequencing data, respectively (see Supplementary data for more details). 
Induced pluripotent stem cells and neuron analysis
Results
Initial data overview
In total we included 21,478 PD cases and 24,388 controls from IPDGC datasets; (Figure 1 ). As expected, the GRS is significantly associated with risk in GBA-negative PD cases compared to controls and interestingly, also in the NDRU-LBD dataset ( Figure 1 and Table 1 ). This effect is highly similar between GBA carrier controls and GBA carrier cases, when excluding GBA and LRRK2 variants from the genetic risk score (Figure 2 and Table 1 ). This effect is consistent in subsets based on all three GBA variants ( Supplementary Figure 1) . Although this was not significant in the (smaller) p.N370S group, the direction and effect size were highly similar to the other GBA variants ( Supplementary Figure 1 , ranging ORs from 1.31 to 1.55). Notably, we do not observe a consistent difference in genetic risk between PD or LBD cases with and without GBA variants when excluding GBA and LRRK2 in the genetic risk (Table 1) .
When assessing the predictive power of the GRS in GBA positive cases versus GBA positive controls (excluding GBA and LRRK2 variants in GRS calculations), these values were slightly lower compared to the reported predictive power of the GRS in PD cases as previously described by Nalls et al (Nalls et al. 2018 Table 7 and Supplementary Figure 2-4) . As expected, the NDRU-LBD dataset performed poorer than the PD cases with an AUC of 0.570 (95%CI 0.540-0.600), supporting the notion of partial overlapping and shared genetic risk between PD and LBD.
SNCA and CTSB loci as genetic modifiers of disease risk in GBA carriers
To identify potential genetic modifiers of GBA-associated PD penetrance, we performed a GWAS comparing PD patients with GBA variants and controls with GBA variants. We first examined the association using all three GBA variants together (p.E326K, p.T369M and p.N370S) in the IPDGC and the UKB dataset, followed by a meta-analysis of both. After meta-analysing the GBA data in both datasets, no genome-wide significant variants were identified (Supplemental Figure 5 ).
When solely examining the 90 PD variants previously identified in a PD case-control GWAS (Nalls et al. 2018) , variants in two PD loci passed Bonferroni multiple test correction for association with PD, SNCA and CTSB. The strongest association was observed with rs356219 in the SNCA locus (meta-P=9.26E-07, OR=1.375, CI95%=1.211-1.563, Table 2 and Supplemental Figure 6 ). In addition to SNCA, the CTSB locus rs1293298 (meta-P=9.74E-06, OR=0.725, CI95%=0.629-0.836, Table 2 and Supplemental Figure 7) was also significantly associated with GBA penetrance after correction for multiple testing ( Supplementary Table   8 ). Additional investigation of these two variants was performed in the 23andMe PD casecontrol dataset and in a WGS dataset (Table 2) . Meta-analyses of these results showed a genome-wide significant P-value (P=2.23E-11) for the SNCA variant and a more significant P-value for the CTSB variant (P=6.34E-6) ( Table 2 and Figure 3 ). The majority of these effects are mostly driven by p.E326K carriers likely due to the larger sample size, but the effect size was consistent for each of the three variants when tested individually in the IPDGC dataset ( Supplementary Table 9 , Supplementary Figure 6 and 7) .
Evidence for a potential genetic interaction between CTSB and GBA
Interestingly, the OR of the CTSB variant rs1293298 association in the GBA GWAS is about 3-fold lower compared to the PD case-control GWAS ( Figure 8) , while for the SNCA variant this was not the case. This suggests a potential interaction between CTSB and GBA. Examining this possibility further resulted in a significant interaction term after meta-analysing effects of the IPDGC and UKB data ( Table 2) . As expected, no consistent significant interaction term was identified between SNCA and GBA (Table 2, Supplemental Figure 9 ). Replication of these results was investigated in the 23andMe and LNG Genomes data for both interactions. In both datasets the interaction terms were not significant, although the direction of effect was the same for CTSB x GBA (Table 2 and Figure 3 ).
Genetic dissection of the CTSB GWAS locus
To evaluate the potential molecular mechanism for increased risk of PD in GBA carriers, we explored gene expression and eQTL datasets for the two significant associated loci, SNCA (rs356219) and CTSB (rs1293298). For the SNCA locus, several previous reports showed that risk variants in this locus likely increase SNCA expression (Pihlstrøm et al. 2018; Soldner et al. 2016) . For the CTSB, no comprehensive assessment has yet been performed. In both the PD GWAS and the GBA GWAS, rs1293298 appears to be the index variant and both GWAS signals appears to be highly similar (Figure 4 A,B ,C).
The protective allele (A) of the CTSB variant rs1293298 increases CTSB expression in the brain in both GTEx and NABEC datasets and was significant in the latest meta-analyses of brain eQTL data ( Supplementary Table 10 ). Results from the NABEC dataset suggest that specific isoforms of CTSB are differentially regulated and the QTL effect is mainly for the most highly expressed transcript (isoform: uc003wuq.3, Supplementary Figure 10) .
Interestingly the QTL signal shows high correlation with the PD GWAS signal ( Figure 4D ).
Exploring post-mortem brain-derived single nuclei RNAseq data showed that CTSB is mainly expressed in neurons and microglia in a pattern that is similar to SNCA expression ( Supplementary Figure 11 ). This suggests that the biological effects of these variants possibly takes place in these cell types, which is in line with pathology and previous literature. We attempted to examine GBA expression levels, but they were too low to assess.
Given the function of Cathepsin B (encoded by CTSB) as lysosomal protease, which is of interest for PD pathogenesis in general (McGlinchey and Lee 2015), we explored other members of the cathepsin family for: 1) genetic association in the most recent PD GWAS; 2) genetic association in GBA GWAS and 3) the presence of an eQTL at each locus. In addition to the peak at CTSB, only CTSE has a PD GWAS peak in close proximity, however this locus is already nominated as the NUCKS1/RAB29 locus ( Supplementary Table 11 ). Interestingly, for almost all cathepsins a brain eQTL has been identified. However, with the exception of CTSB, none of the eQTLs were associated with PD ( Supplementary Table 11 figure 12) . We observed a significantly lower (P = 0.0291; unpaired t-test, n=6) level of processed Cathepsin B protein in GBA variant carriers compared to cells without GBA variants (GBA WT = 0.528 ± 0.0930; GBA p.N370S = 0.263 ± 0.0467) ( Figure 5) . These results show that the GBA variant carriers have reduced levels of mature Cathepsin B which may result in even lower lysosomal protease activity and increased accumulation of protein aggregates in neurons. Although the forebrain neurons carrying the GBA variant did not have increased levels of α -synuclein ( Supplementary Figure 13) it is possible that the overall reduction in lysosomal proteases allows for a faster accumulation of α -synuclein aggregates as neurons age. Figure 6C ). Of note, the LRRK2 p.G2019S variant was also identified in 14 GBA carriers (9 p.N370S and 5 p.E326K carriers) and did not seem to influence the AAO P=0.44 (Linear regression, Beta=2.41, SE=3.15, GBA-PD-LRRK2 p.G2019S carriers average=63.86, SD=10.87 vs GBA-PD-non-LRRK2 p.G2019S average=60.29, SD=11.80), which is consistent with previous findings, although power was limited given the small number of included individuals (Yahalom et al. 2018 ).
Genetic modifiers of age at onset in GBA associated Parkinson's disease cases
To identify potential GBA AAO modifiers, we performed a GWAS using AAO as phenotype in all GBA positive PD cases (n=1,353). No genome-wide hits were identified, most likely due to the relatively low sample size. When investigating previously identified PD loci, no variants passed Bonferroni correction. However, nominally significant signals were identified for several PD loci, including SNCA and TMEM175 ( Supplementary Table 12 ). Similar to PD in general, the PD-GRS is significantly associated with a lower AAO in GBA carriers ( Figure   6A ) (Blauwendraat et al. 2019 ). This effect was mainly driven by p.E326K carriers.
However, both p.T369M and p.N370S carriers also show the same trend towards lower AAO with a similar effect size that is close to significance likely due to lower sample numbers ( Figure 6B) . This association was similar in an independent p.N370S Ashkenazi Jewish ancestry dataset, again demonstrating the same general trend and similar effect size. A metaanalysis of the three tested GBA variants resulted in a significant P-value of 0.0050 (Figure 6,   Supplementary Figure 14) .
Discussion
In the current study, we analysed multiple large datasets to examine whether genetic variants affect the penetrance and AAO of GBA-associated neurodegeneration. Our data show that at least 7% of the European PD population carries a common protein coding GBA risk variant versus ~4.5% of the general population. It is noteworthy that this number is an underestimation because in some datasets p.T369M and p.N370S were not genotyped or reliably imputed, and rarer disease-linked GBA variants were not captured. For LBD, these numbers are likely to be higher as seen in the NDRU-LBD dataset with ~13% of the LBD cases carrying a GBA variant.
One of the major findings of this study is that PD and LBD cases with a GBA variants often also carry a substantial number of other PD associated risk variants, which may modify disease risk and AAO. Pre-trial genetic analysis could assist in identifying those at higher risk for developing PD or LBD outside of the risk accounted for at the GBA target. Therefore, future clinical trials involving GBA carriers should include a comprehensive genetic assessment prior to enrolment, as we have previously suggested (Leonard et al. 2018 ).
Additionally, disease predictions based on current genetic knowledge alone are not sufficient;
larger datasets are needed and more non-genetic data, such as family history and smell test results can significantly improve disease prediction (Nalls et al. 2015c ).
The link between PD and lysosomal pathways has already been established by both genetic and functional studies (Gan-Or et al. 2015b; Robak et al. 2017; Ysselstein et al. 2019) .
Moreover, in the latest PD GWAS (Nalls et al. 2018 ) numerous lysosomal and autophagyrelated genes were associated with PD, emphasizing the central role of the lysosomalautophagy pathway in disease. Interestingly, the two main loci identified that influence disease risk in GBA carriers are variants in close proximity to SNCA and CTSB (rs356219 and rs1293298), both implicated in the lysosomal autophagy pathway. The SNCA locus is wellstudied and the current hypothesis is that variants in this locus increase SNCA expression of either total α -synuclein or specific mRNA isoforms, resulting in an increased risk of PD (Pihlstrøm et al. 2018; Soldner et al. 2016) .
For the CTSB locus, no functional studies have been performed to dissect this locus in PD to date, although several genetic studies have nominated CTSB as causal gene in this region via either QTL analyses or Mendelian randomization (Li et al. 2019; Nalls et al. 2018 ).
Therefore, it remains unclear whether CTSB is the actual causal gene in this locus. However, there is evidence linking CTSB to PD pathways. In this study, we see a decrease in processed Cathepsin B protein levels in iPSC-derived neurons from GBA variant carriers compared to non-carriers, suggesting a further reduction in lysosomal protease function in these cases.
Depletion of TMEM175, another lysosomal gene associated with PD, significantly decreases protein expression and enzyme activity of Cathepsin B in rat hippocampal neurons (Sarah Jinn et al. 2017; S. Jinn et al. 2019) . Cathepsin B has also been suggested to be involved in α synuclein lysosomal degradation (McGlinchey and Lee 2015) . Moreover, ceramide, which is one of the lipids produced by GCase, has been shown to be an activator of Cathepsin Brelated pathways (F. Liu et al. 2016) . Overall, these results fit with the general model that GBA risk variant carriers have impaired lysosomal function due to reduced or abolished GCase activity (Alcalay (Alcalay et al. 2015) . The independent associations of the SNCA and CTSB loci with GBA associated PD suggest that increased SNCA expression and/or decreased CTSB mRNA expression further impair lysosomal function, resulting in an increased risk of PD. Additionally, we identified that Cathepsin B protein levels are reduced in p.N370S neurons compared to wildtype. Overall, these findings suggest that Cathepsin B might play a larger role in PD than previously thought and that increasing CTSB/Cathepsin B levels could be a potential therapeutic strategy. However, extensive functional in vitro and in vivo work is needed to validate these effects.
Despite the large datasets included in this study, it has several limitations. First, only one genome-wide significant locus was identified (SNCA), most likely due to the lack of power caused by the relatively low number of GBA variant carriers available. However, when we sought to reduce the burden of genome-wide correction by examining previously implicated PD risk loci, a significant association with the CTSB locus was identified. Second, the majority of the analyses were based on aggregated genotype data derived from several different genotyping arrays and centers/countries. As such, some datasets did not contain data on all three of the GBA variants of interest. It is also important to consider that different centers/countries might have used different measures of AAO or age at diagnosis and that included controls may develop PD at a later age. However, using the current data, we are still able to identify large effects, such as those driven by the GRS. Larger future initiatives specifically focused on GBA carriers will resolve these limitations and are needed to confirm these associations. Third, because the majority of the data included here were also used in the most recent PD GWAS meta-analysis (Nalls et al. 2018) ; there could be a bias towards the identification of known PD risk signals in this GBA dataset. We addressed this potential bias by looking for replication in several datasets that have not been included in the most recent PD GWAS meta-analysis, such as the UKB PD cases, the LBD dataset and the McGill GBA dataset. Unfortunately, we did not have a replication dataset for the GBA AAO results, so these results require replication in an independent dataset. Finally, some datasets might have excluded known GBA carriers prior to genotyping, which would result in an underestimation of total GBA carriers and the associated risk estimates. Of note, another relatively common GBA variant p.L444P (rs421016) is currently not imputable, since it is not included in the HRC reference panel and is in a complex region of the genome with a highly similar pseudogene.
Despite these limitations, several conclusions can be drawn from our results. First, the risk of PD in GBA carriers is influenced by specific variants at loci that are known to be associated more generally with PD risk, including SNCA and CTSB, the latter possibly through interaction with GBA. In addition, GBA associated risk is significantly affected by the GRS; in the initial used datasets. Additional datasets were assessed and overall both P-values 20 became more significant. The interaction effects between the two variants and GBA was not replicated in the external datasets. GBA carrier status excluding GBA in the genetic risk score calculation. Genetic risk score differences between GBA negative controls, GBA negative Parkinson's disease or Lewy body dementia cases, GBA positive controls and GBA positive cases when excluding the GBA region and LRRK2 p.G2019S from the calculations. In each dataset, a highly similar effect is observed clearly separating the cases and controls. However, there is no clear separation between GBA cases and GBA negative cases or GBA negative controls and GBA positive controls. Critical revision of the manuscript for important intellectual content: All
